Given prior studies that reported synergy with cytotoxic agents, we then investigated the activity of anti-CD47 therapy combined with PARP inhibition compared to control and monotherapy both in-vitro and in-vivo in BRCA mutated ovarian cancer models. The gene discussed is CD47; the disease is ovarian cancer.